Irhythm Technologies Intrinsic Value – iRhythm Technologies Revolutionizes Arrhythmia Detection With AI and Machine Learning

May 27, 2023

Trending News 🌥️

IRHYTHM ($NASDAQ:IRTC): iRhythm Technologies is revolutionizing the detection of arrhythmia, a potentially life-threatening heart condition, with the use of Artificial Intelligence (AI) and Machine Learning. AI and Machine Learning are used to analyze electrocardiogram (ECG) data to detect arrhythmia signals and accurately assess a patient’s risk for arrhythmia. This cutting-edge technology has made it possible to detect arrhythmia earlier and more accurately than ever before. iRhythm Technologies is a healthcare company focused on using AI and Machine Learning to improve the detection of arrhythmia. The company’s flagship product, Zio, is an ambulatory ECG device that collects and transmits data to the iRhythm cloud for analysis. Zio enables physicians to quickly and accurately diagnose arrhythmia and provide treatment.

The company is also developing a suite of AI-driven software products to help physicians detect, diagnose, and monitor a wide range of cardiac conditions. iRhythm Technologies’ innovative approach to healthcare has made them a leader in arrhythmia detection. Their cutting-edge technology is helping to improve patient outcomes by providing earlier and more accurate diagnosis of arrhythmia. With the continued development of their AI-driven software products, iRhythm Technologies is positioned to become an industry leader in cardiac care.

Price History

On Friday, their stock opened at $121.3 and closed at $119.3, representing a 1.4% decrease from the previous closing price of $120.9. The company is leveraging AI and machine learning to identify patterns in heart rhythm data to accurately and quickly detect arrhythmias. This cutting-edge technology is offering unprecedented accuracy and speed in arrhythmia detection, and is expected to revolutionize the medical industry. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Irhythm Technologies. More…

    Total Revenues Net Income Net Margin
    429.98 -104.66 -24.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Irhythm Technologies. More…

    Operations Investing Financing
    -14.88 -40.09 12.98
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Irhythm Technologies. More…

    Total Assets Total Liabilities Book Value Per Share
    421.7 199.87 7.28
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Irhythm Technologies are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    23.2% -23.6%
    FCF Margin ROE ROA
    -11.1% -27.4% -15.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Irhythm Technologies Intrinsic Value

    At GoodWhale, we believe that analyzing fundamentals is an essential part of making successful investments. That’s why we offer tools to help you dive deeper into the fundamentals of IRHYTHM TECHNOLOGIES. Our proprietary Valuation Line is a great place to start, calculating the fair value of IRHYTHM TECHNOLOGIES at around $168.2. With this information, you can see that the current market price of IRHYTHM TECHNOLOGIES shares is trading at $119.3, which is undervalued by 29.1%. This could be an opportunity to buy a potentially undervalued stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition between iRhythm Technologies Inc and its competitors is fierce. Each company is striving to develop the best technology and products to help cancer patients. While iRhythm Technologies Inc is focused on developing products to help patients with cancer, its competitors are also working hard to develop their own products to help cancer patients.

    – Advanced Oncotherapy PLC ($LSE:AVO)

    Advanced Oncotherapy PLC is a UK-based company that provides proton therapy treatment for cancer patients. The company has a market capitalization of 114.21 million as of 2022 and a return on equity of -27.6%. Advanced Oncotherapy PLC is a provider of proton therapy, which is a type of cancer treatment that uses protons to destroy cancer cells. The company’s proton therapy system is called the LIGHT system, which is currently in clinical trials.

    – VeriTeQ Corp ($OTCPK:VTEQ)

    VeriTeQ Corp is a provider of digital vaccine and health passport technology solutions. The company’s solutions are designed to increase patient safety and improve clinical outcomes by providing real-time visibility into the vaccination and immunization status of patients. VeriTeQ’s vaccine and health passport technology is used by healthcare providers, pharmaceutical companies, and government agencies to track and verify the vaccination and immunization status of patients.

    – Bone Biologics Corp ($NASDAQ:BBLG)

    Biologics Corp is a company that develops and commercializes biologic products for the treatment of orthopedic diseases and conditions. The company has a market cap of 7.46M and a ROE of -16.65%.


    IRHYTHM Technologies is an innovative health technology company that uses AI and machine learning to revolutionize the detection and management of arrhythmias. Through its proprietary Zio platform, IRHYTHM provides accurate, actionable data to clinicians and patients, allowing for quick diagnosis and effective treatments. With its cutting-edge healthcare solutions, investors have the potential to benefit from the company’s growth in the years to come.

    IRHYTHM possesses deep expertise in medical device development, data science, and regulatory approval, making it well-positioned to capitalize on the potential of digital health innovation. As a result, investors looking to gain exposure to the medical device industry should strongly consider investing in IRHYTHM Technologies.

    Recent Posts

    Leave a Comment